NASDAQ$COGT
Cogent Biosciences Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Cogent Biosciences reported financial results for Q4 2024 and provided a business update.
Cogent Biosciences reported its Q4 and full year 2024 financial results, highlighting upcoming data readouts from bezuclastinib pivotal clinical trials and a strong cash balance sufficient to fund operations into late 2026.
- Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025.
- APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025.
- Top-line results from PEAK trial in 2nd-line GIST patients expected by end of 2025.
- $312 million is considered sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025.
Headline financials
Revenue & EPS history
Cogent Biosciences · Revenue · Quarterly
$0
Forward guidance
Cogent Biosciences anticipates several milestones for 2025, including clinical trial results and regulatory submissions.
Tailwinds
- SUMMIT top-line results expected in July 2025
- APEX top-line results expected in the second half of 2025
- PEAK top-line results expected by the end of 2025
- Planned submission of Cogent’s first NDA for bezuclastinib by the end of 2025
- Initiate Expanded Access Programs in the first quarter of 2025 in the United States for SM and GIST patients
Headwinds
- Clinical trial results are subject to inherent uncertainties
- Regulatory submissions and approvals are not guaranteed
- The company's cash runway is dependent on various factors and may not extend as far as anticipated
- Development of pipeline programs involves significant risks and uncertainties
- The company's forward-looking statements are subject to material risks and uncertainties
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+0.9%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+4.5%
Avg return
30 days after
65%
20 / 31 earnings
Positive
+17.8%
Q3 2018
Best reaction
-24.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -5.3% | -10.6% | |
| Q3 2025 | -4.4% | -9.1% | +140.2% | |
| Q2 2025 | -5.8% | -9.0% | +7.4% | |
| Q1 2025 | +2.7% | +4.4% | +48.4% | |
| Q4 2024 | -6.3% | +0.9% | -11.4% | |
| Q3 2024 | +0.0% | -14.4% | -19.8% | |
| Q1 2024 | +0.4% | -0.1% | +11.1% | |
| Q4 2023 | +0.7% | -2.8% | -12.4% | |
| Q3 2023 | +3.9% | +3.8% | -2.7% | |
| Q2 2023 | +7.3% | +8.8% | +9.4% | |
| Q1 2023 | -1.5% | -2.6% | -2.9% | |
| Q4 2022 | +0.7% | -5.1% | -13.7% | |
| Q3 2022 | -5.7% | -8.5% | -2.6% | |
| Q2 2022 | +9.6% | +12.1% | +32.7% | |
| Q1 2022 | -24.0% | -26.8% | -10.6% | |
| Q4 2021 | +4.5% | +28.4% | +64.6% | |
| Q3 2021 | +13.7% | +12.1% | -9.9% | |
| Q2 2021 | +5.4% | +13.4% | +3.3% | |
| Q1 2021 | +1.7% | +4.9% | +4.0% | |
| Q4 2020 | +5.9% | +5.5% | +9.0% | |
| Q3 2020 | +13.2% | +9.8% | +14.9% | |
| Q2 2020 | -11.4% | -11.0% | -8.3% | |
| Q1 2020 | +0.5% | +17.9% | +37.1% | |
| Q4 2019 | -3.1% | -15.5% | -18.6% | |
| Q3 2019 | -10.2% | -32.6% | -52.1% | |
| Q2 2019 | +4.4% | +9.3% | +9.0% | |
| Q1 2019 | +0.2% | -1.1% | -26.2% | |
| Q4 2018 | +8.1% | +5.4% | -12.3% | |
| Q3 2018 | +17.8% | +18.5% | -25.0% | |
| Q2 2018 | -5.9% | -12.8% | -27.3% | |
| Q1 2018 | +4.0% | +12.4% | +13.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro